Treatment satisfaction with siponimod in patients with advancing relapsing multiple sclerosis: Interim results of the EXCHANGE study

被引：0
|
作者：
Cohan, S. L. [1 ,2 ]
Fox, R. J. [3 ]
Mao-Draayer, Y. [4 ]
Bar-Or, A. [5 ,6 ]
Cox, G. Mavrikis [7 ]
Meng, X. [7 ]
Cruz, L-A [7 ]
Weinstock-Guttman, B. [8 ]
机构：
[1] Providence Hlth & Serv, Providence Brain & Spine Inst, Portland, OR USA
[2] Providence Hlth & Serv, Providence Multiple Sclerosis Ctr, Portland, OR USA
[3] Cleveland Clin, Neurol Inst, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Univ Michigan, Multiple Sclerosis Ctr, Autoimmun Ctr Excellence, Ann Arbor, MI 48109 USA
[5] Univ Penn, Perelman Sch Med, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1145
引用
收藏
页码：901 / 902
页数：2
相关论文
共 50 条
  • [21] Siponimod for the treatment of secondary progressive multiple sclerosis
    Dumitrescu, Laura
    Constantinescu, Cris S.
    Tanasescu, Radu
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 143 - 150
  • [22] Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study
    Wray, Sibyl
    Jacques, Francois
    Miller, Tamara A.
    Nicholas, Jacqueline A.
    Arroyo, Rafael
    Travis, Lori
    Khatri, Bhupendra
    Chirieac, Magdalena
    Gandhi, Roopali
    Roesch, Nora
    Rodrigues, Amelie
    Melas-Melt, Lydie
    Rawlings, Andreea M.
    Hunter, Samuel F.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2022, 8 (04)
  • [23] Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
    Brochet, Bruno
    Hupperts, Raymond
    Langdon, Dawn
    Solari, Alessandra
    Piehl, Fredrik
    Lechner-Scott, Jeannette
    Montalban, Xavier
    Selmaj, Krzysztof
    Valis, Martin
    Rejdak, Konrad
    Havrdova, Eva K.
    Patti, Francesco
    Alexandri, Nektaria
    Nolting, Axel
    Keller, Birgit
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [24] A THREE MONTH INTERIM ANALYSIS OF TREATMENT SATISFACTION WITH FINGOLIMOD IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK: THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY
    Adlard, N.
    Brisbane, F.
    Watson, J.
    Bishop-Bailey, A.
    Kroes, M.
    VALUE IN HEALTH, 2017, 20 (09) : A728 - A728
  • [25] A real-world, retrospective study to assess the effectiveness and safety of siponimod in Chinese patients with relapsing forms of multiple sclerosis
    Zhang, Yao
    Liu, Hongbo
    Zhou, Ming
    Li, Zheng
    Li, Bingbing
    Cai, Min
    Shi, Xiaofang
    Liu, Lyra
    Lin, Anne
    Xu, Yan
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1100 - 1100
  • [26] The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
    Martin Vališ
    Anat Achiron
    Hans Peter Hartung
    Jan Mareš
    Veronika Tichá
    Pavel Štourač
    Simona Halusková
    Francesco Angelucci
    Zbyšek Pavelek
    Drugs in R&D, 2023, 23 : 331 - 338
  • [27] Argentinean registry of patients with relapsing remitting multiple sclerosis treated with fingolimod (REAL): design and results of interim analysis
    Seifer, G.
    Kuperman, G. A.
    Villa, A.
    Caceres, F.
    Herrera, G.
    Rey, R.
    Parada Marcilla, M.
    Calvo Vildoso, C.
    Arguello, G.
    Parisi, V.
    Neme, R.
    Sinay, V.
    Blasco, J. M.
    Labal, P.
    Burgos, M.
    Deri, N.
    Linares, R.
    Vetere, S.
    Jacobo, M.
    Golberg, M.
    Castronuovo, A.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 165 - 166
  • [28] Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Arnould, Sophie
    Sidorenko, Tatiana
    Wolf, Christian
    Wallstrom, Erik
    Dahlke, Frank
    NEUROLOGY, 2017, 88
  • [29] Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Vermersch, Patrick
    Bar-Or, Amit
    Gold, Ralf
    Magnusson, Baldur
    Rouyrre, Nicolas
    Meier, Daniela Piani
    Tomic, Davorka
    Karlsson, Goeril
    Dahlke, Frank
    Kappos, Ludwig
    NEUROLOGY, 2018, 90
  • [30] Interim Analysis of a Phase III Long Term Extension Study of Ponesimod in Relapsing Multiple Sclerosis: Safety Results
    Rosas-Ballina, M.
    Wooller, A.
    Larbalestier, A.
    Ait-Tihyaty, M.
    Vaclavkova, A.
    Sidorenko, T.
    Montalban, X.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 292 - 293
12345